bf/NASDAQ:IOVA_icon.jpeg

NASDAQ:IOVA

Iovance Biotherapeutics, Inc.

  • Stock

3.33

−7.24%

1.10

USD last updated 13/08 01:59:42

Last Close

2.23

12/08 22:32

Market Cap

2.18B

Beta: 0.20

Volume Today

10.67M

Avg: 3.51M

PE Ratio

−4.56

PFCF: −7.39

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, ...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -0.8-0.6-0.4-0.22019-11-042020-12-302022-05-052023-11-072024-11-07

    Revenue (Estimate*)

    20M40M60M80M2019-11-042020-12-302022-05-052023-11-072024-11-07

    *Estimate based on analyst consensus